Please login to the form below
Orion
This page shows the latest Orion news and features for those working in and with pharma, biotech and healthcare.
Bayer’s Nubeqa receives MHRA approval to treat metastatic prostate cancer
Nubeqa, developed jointly by Bayer and Orion, is an oral androgen receptor inhibitor with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity,
Latest news
-
Novartis’ Leqvio shows sustained efficacy and safety for cardiac patients
In ORION-3, an open-label extension of the phase 2 ORION-1 trial, LDL-C level reduction was sustained over the four-year study period, with Leqvio-treated patients achieving
-
Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
Bayer’s development partner, Orion, reported that prostate cancer remains the second leading cancer-related cause of death among men in the US, with up to one-third of patients developing
-
UK’s NICE recommends anti-cholesterol Leqvio for high-risk patients
Professor Kausik Ray of Imperial College London, who was lead investigator on the pivotal ORION-10 and ORION-11 trials for Leqvio, said that the drug brought LDL-C levels down
-
Novartis announces delay in UK cholesterol drug study
In January 2020, Novartis announced that it had teamed up with the UK’s National Health Service (NHS) on a clinical trial – ORION-4 – of the drug. ... Tsai addressed the ORION-4 delays amid a discussion of Novartis’ first quarter results for 2021.
-
Janssen’s Erleada improves survival in certain advanced prostate cancer patients
Bayer/Orion’s Nubeqa (darolutamide) is a more recent competitor and it has been approved for the treatment of nmCRPC in men.
More from news
Approximately 3 fully matching, plus 36 partially matching documents found.
Latest Intelligence
-
Deal Watch table for June 2014
75. Orion/ Bayer. Co-development, option to co-promote in Europe. OraQuick HCV rapid test in US.
-
Pharma deals during June 2014
Financial terms were not disclosed but include milestone and royalties. Staying with the mid-caps and turning to prostate cancer, Bayer and Orion entered into a joint development deal for ... The companies will jointly fund the phase III trials. Orion
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Orion appoints VP of oncology, R&D
He said: “My new position at Orion allows me to maintain and deepen my research focus, which is to develop such treatments for cancer patients wherever they live. ... I hope that my long background in the academia will help in the initiation of new
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Latest from PMHub
-
Leading NHS suppliers highlighted in shortlist for new HSJ awards
Philips. Intercity Technology. Orion Health and Temple Street Children’s University Hospital.
-
Creative Medical Research
Address:. 9 Pegasus. Orion Court , Great Blakenham. Ipswich. IP6 0LW.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Putting Skin in the Game at AAD 2023
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- NHS England announces rare genetic disorder fast-tracking service
- NICE sees ‘promise’ in four UTI tests that could help in fight against AMR
- Connectome competitiveness
- Humancomms for humancare?
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- Genmab hires first chief operating officer
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
